Nanotechnology Now

Our NanoNews Digest Sponsors
Heifer International

Wikipedia Affiliate Button

Home > Press > Discovery may lead to precision-based strategy for triple negative breast cancer: Indiana University researcher develops promising nanotechnology approach for treatment of aggressive form of disease

Xiongbin Lu, Ph.D., is a nationally recognized cancer biologist and the Vera Bradley Foundation Professor of Breast Cancer Innovation at Indiana University School of Medicine.

CREDIT
Indiana University School of Medicine
Xiongbin Lu, Ph.D., is a nationally recognized cancer biologist and the Vera Bradley Foundation Professor of Breast Cancer Innovation at Indiana University School of Medicine. CREDIT Indiana University School of Medicine

Abstract:
Unlike the three most common forms of breast cancer, triple negative breast cancer has no currently approved targeted therapies for treatment. That was one of the reasons it was chosen as a disease area of focus for the Indiana University Precision Health Grand Challenge initiative, aimed to research and develop better treatments, cures or preventions, as quickly as possible.

Discovery may lead to precision-based strategy for triple negative breast cancer: Indiana University researcher develops promising nanotechnology approach for treatment of aggressive form of disease

Indianapolis, IN | Posted on March 22nd, 2019

Xiongbin Lu, PhD, a researcher in the Vera Bradley Foundation Center for Breast Cancer Research at Indiana University School of Medicine, working in collaboration with researchers from the University of Maryland, recently reported several important findings related to triple negative breast cancer and its treatment future, in the prestigious journal Nature Nanotechnology.

According to the paper now available online, TP53 is the most frequently mutated gene in triple negative breast cancer, meaning it is fueling the growth of this aggressive form of breast cancer. However, the problem with trying to target mutated TP53, specifically, is that it is not a druggable target, because of its potential toxicity - or ability to kill - nearby healthy cells.

In response, the scientists went searching for the next likely suspect to target, and found a neighboring gene to TP53, known as POLR2A, which is a viable target, but required some additional effort.

Lu, also a researcher at the Indiana University Melvin and Bren Simon Cancer Center, said, "Think of POLR2A as both a checking and savings account. In a healthy cell, both accounts exist. In a triple negative breast cancer cell, only the checking account exists due to the partial deletion of this particular essential gene, and if you take it away, the individual cannot survive."

However, utilizing nanotechnology (scientific technology on a microscopic scale), the group created what is known as a nano-bomb targeting POLR2A. The nano-bomb is created in a form that is stable in serum and when an instance of the POLR2A inhibitor-containing nano-bomb is delivered into a triple negative breast cancer cell, the bomb grows to 100 times its normal size and through a controlled release, kills only the cancerous cell, leaving the healthy cells alive. Essentially, using Dr. Lu's analogy, "leaving the checking account open."

Lu and a collaborator have patented this nanotechnology approach, which also has potential implications in other cancers that display the mutated TP53 gene, such as ovarian, lung and colorectal cancer. "We're still in the early stages of research, but I am excited about this approach and its potential to lead to a targeted therapy option for women with triple negative breast cancer," Lu said.

####

About Indiana University
Indiana University School of Medicine is one of the nation's premier medical schools and is a leader and innovator in medical education, research and clinical care. The country's largest medical school, IU School of Medicine educates more than 1,700 medical and graduate degree students on nine campuses in Indiana, and its faculty holds nearly $340 million in research grants and contracts, to advance the School's missions and promote life sciences. For more information, please visit medicine.iu.edu.

For more information, please click here

Contacts:
Christine Drury

317-278-2854

Copyright © Indiana University

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related Links

RELATED JOURNAL ARTICLE:

Related News Press

News and information

A light-activated remote control for cells April 17th, 2019

NEXUS 2019: Global Summit on Energy Materials and Green Nanotechnology April 16th, 2019

Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease April 15th, 2019

New microscopy method provides more details about nanocomposites April 12th, 2019

Cancer

'Nanobodies' from alpacas could help bring CAR T-cell therapy to solid tumors: Unusually small antibodies, targeted to the tumor micro-environment, curb melanoma and colon cancer in mouse models April 11th, 2019

Magnetic nanoparticles can 'burn' cancer cells: Magnetic hyperthermia is still a highly experimental cancer treatment, but new research shows that the therapy is tunable April 7th, 2019

Nanobiotix Receives European Market APPROVAL for Cancer Therapy Hensify (NBTXR3) April 3rd, 2019

Combination of first-in-class NBTXR3, radiotherapy, and anti-PD-1 immunotherapy demonstrate efficacy in treating resistant pre-clinical in vivo models of lung cancer April 3rd, 2019

Govt.-Legislation/Regulation/Funding/Policy

A light-activated remote control for cells April 17th, 2019

Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease April 15th, 2019

New microscopy method provides more details about nanocomposites April 12th, 2019

'Nanobodies' from alpacas could help bring CAR T-cell therapy to solid tumors: Unusually small antibodies, targeted to the tumor micro-environment, curb melanoma and colon cancer in mouse models April 11th, 2019

Possible Futures

A light-activated remote control for cells April 17th, 2019

Oregon scientists drill into white graphene to create artificial atoms: Patterned on a microchip and working in ambient conditions, the atoms could lead to rapid advancements in new quantum-based technology April 12th, 2019

2D gold quantum dots are atomically tunable with nanotubes April 11th, 2019

'Nanobodies' from alpacas could help bring CAR T-cell therapy to solid tumors: Unusually small antibodies, targeted to the tumor micro-environment, curb melanoma and colon cancer in mouse models April 11th, 2019

Nanomedicine

A light-activated remote control for cells April 17th, 2019

Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease April 15th, 2019

Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress™ April 12th, 2019

'Nanobodies' from alpacas could help bring CAR T-cell therapy to solid tumors: Unusually small antibodies, targeted to the tumor micro-environment, curb melanoma and colon cancer in mouse models April 11th, 2019

Discoveries

A light-activated remote control for cells April 17th, 2019

Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease April 15th, 2019

New microscopy method provides more details about nanocomposites April 12th, 2019

Oregon scientists drill into white graphene to create artificial atoms: Patterned on a microchip and working in ambient conditions, the atoms could lead to rapid advancements in new quantum-based technology April 12th, 2019

Announcements

A light-activated remote control for cells April 17th, 2019

NEXUS 2019: Global Summit on Energy Materials and Green Nanotechnology April 16th, 2019

Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease April 15th, 2019

New microscopy method provides more details about nanocomposites April 12th, 2019

Grants/Sponsored Research/Awards/Scholarships/Gifts/Contests/Honors/Records

'Nanobodies' from alpacas could help bring CAR T-cell therapy to solid tumors: Unusually small antibodies, targeted to the tumor micro-environment, curb melanoma and colon cancer in mouse models April 11th, 2019

2D borophene gets a closer look: Rice, Northwestern find new ways to image, characterize unique material April 11th, 2019

'Deep learning' casts wide net for novel 2D materials: Rice U. engineers show faster techniques to model atom-flat materials for bottom-up design April 10th, 2019

Odd reaction creates a stir in the lab: Rice University researchers find using certain stir bars can create laboratory errors March 29th, 2019

Nanobiotechnology

A light-activated remote control for cells April 17th, 2019

Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease April 15th, 2019

Arrowhead Presents Clinical Data on JNJ-3989 (ARO-HBV) at The International Liver Congress™ April 12th, 2019

'Nanobodies' from alpacas could help bring CAR T-cell therapy to solid tumors: Unusually small antibodies, targeted to the tumor micro-environment, curb melanoma and colon cancer in mouse models April 11th, 2019

Research partnerships

2D borophene gets a closer look: Rice, Northwestern find new ways to image, characterize unique material April 11th, 2019

'Deep learning' casts wide net for novel 2D materials: Rice U. engineers show faster techniques to model atom-flat materials for bottom-up design April 10th, 2019

Squeezed nanocrystals: A new model predicts their shape when blanketed under graphene April 5th, 2019

Nanoscribe is Technology Partner of the Research Project MiLiQuant: 3D microfabrication meets quantum technology - Miniaturized light sources for industrial use in the fields of quantum sensor technology and quantum imaging April 1st, 2019

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project